| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3192755 | Annals of Allergy, Asthma & Immunology | 2010 | 6 Pages |
Abstract
The half-life of the same pC1-INH concentrate reported in a previous study was confirmed by this retrospective population pharmacokinetic analysis in patients treated for acute HAE attacks. In contrast to other treatment options with shorter half-lives, the long half-life of pC1-INH concentrate may provide an extended period of protection, even after the symptoms of an attack have subsided.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Jonathan A. MD, Bruce MD, Robyn J. MD, Richard L. MD, PhD, Againdra K. MD, David S. MD, Krystyna MD, Avner MD, Dumitru MD, Todor MD, Vesna MD, Peter C. PhD, Fritz MS, Timothy J. DO,